INTRODUCTION {#Sec1}
============

Efforts to identify people early in the course of HIV infection in the United States have had limited success. Approximately half of patients are identified with HIV only when they have advanced disease.[@CR1],[@CR2] Recent CDC estimates indicate 38.3% of patients had received an AIDS diagnosis within a year of their HIV diagnosis; another 6.7% received an AIDS diagnosis from 1 to 3 years after their HIV diagnosis.[@CR3] The Centers for Disease Control and Prevention (CDC) estimates that approximately 232,000 people who have HIV in the US are not aware they are infected.[@CR4] Approximately 21% of infected individuals across the US are unaware of their HIV status;[@CR5] the transmission rate from HIV-infected individuals unaware of their infection is up to 3.5 times higher that from individuals who are aware of their infection.[@CR6] The toll from this lack of awareness is high: over 14,000 new infections per year are caused by people who do not know they have HIV.[@CR7],[@CR8]

Based on these findings, and on studies that indicate that risk-based screening fails to identify many people with HIV, the CDC now recommends that screening for HIV should be performed routinely for all patients between the ages 13-64 in health-care settings.[@CR1] A recent guidance statement from the American College of Physicians also recommends routine screening.[@CR9] Routine screening for HIV is cost-effective, even with prevalence as low as 0.05% to 0.1%,[@CR10]--[@CR12] which likely includes most health-care settings. Screening is also cost-effective for patients up to the age of 75, if it is performed with streamlined counseling.[@CR13]

Despite the strong rationale for screening, there are many potential barriers to implementation of routine testing for HIV, and even patients at high-risk often are not tested.[@CR7],[@CR14]--[@CR16] We report here the cost-effectiveness of three alternative strategies for implementing HIV testing that were evaluated previously in a randomized control trial.[@CR17] The three strategies are traditional HIV counseling and testing, nurse-initiated routine screening with traditional counseling and testing, and nurse-initiated routine screening with streamlined counseling and rapid HIV testing. The cost-effectiveness of these strategies is important because the randomized trial demonstrated that nurse-initiated routine screening with streamlined counseling and rapid HIV testing results in substantially higher testing rates, higher rates of receiving test results, and equivalent sexual risk behaviors and HIV knowledge post-intervention, when compared to traditional HIV counseling and testing.[@CR17]

METHODS {#Sec2}
=======

We estimated the health and economic effects of strategies to increase HIV testing rates and receipt of results using a decision model. We followed the recommendations of the Panel on Cost-Effectiveness in Health and Medicine for performing and reporting a cost-effectiveness analysis.[@CR18] We used the perspective of a perfect insurer,[@CR19] which uses costs to the insurer and patient, and corresponds to what most studies term a societal perspective. Both costs and benefits were discounted at a 3% annual rate,[@CR20] and patients were followed for their lifetime.

We adapted a Markov model[@CR21],[@CR22] developed to assess the cost-effectiveness of voluntary HIV screening in health-care settings[@CR12],[@CR13] using Decision Maker software. Calibration and validation of the decision model and its outputs occurred as an iterative process throughout its development. HIV natural history and treatment effects were compared to published estimates, and our assumptions were modified as needed to calibrate to these data.[@CR11],[@CR23]--[@CR25]

The model tracked a cohort of patients over their lifetime. Patients were offered HIV testing and received their results through one of three methods: (1) traditional HIV testing and counseling (Model A), (2) nurse-initiated screening with traditional HIV testing and counseling (Model B), or (3) nurse-initiated screening with rapid HIV testing and streamlined counseling (Model C) (Fig. [1](#Fig1){ref-type="fig"}). For each strategy, we replicated the rates of HIV testing and receipt of results observed in the RCT.[@CR17] Each month, the model assessed the patients' HIV status, whether their HIV was identified, the clinical course of HIV disease, the costs and consequences of HIV transmission and of highly active antiretroviral therapy (HAART) for patients identified with HIV and eligible for treatment. Estimates for HIV natural history, treatment, transmission of HIV and quality-of-life were derived from high-quality published literature and expert clinical judgment. Our methods have been described previously[@CR12],[@CR13] ([Appendix available online](#MOESM1){ref-type=""}) Figure 1Schematic representation of decision model. The square node at the left represents the initial decision to initiate HIV testing through a physician-based or nurse-based strategy, and then whether traditional or streamlined counseling is performed. Patients in each strategy can then accept or refuse HIV screening. Once screened for HIV, patients could receive their test results or not. All patients regardless of their testing status then enter the Markov model (gray box). In all strategies, patients who do not receive screening through their initial interaction with the physician or nurse may be screened at a later date through symptom-based case finding. We assumed that the frequency with which case finding occurred was 80% annually below a CD4 count of 50 cells per cubic millimeter, linearly related to the CD4 count between 50 and 350 cells per cubic millimeter, and not relevant (0%) with a CD4 count of more than 350 cells per cubic millimeter, when patients were assumed to be asymptomatic. Model A = traditional HIV counseling and testing; Model B = nurse-initiated screening with traditional HIV testing and counseling; Model C = nurse-initiated screening with rapid HIV testing and streamlined counseling.

Patient Population {#Sec3}
------------------

Our cohort was modeled to reflect the patients in the RCT.[@CR17] The trial included 251 patients from two Department of Veterans Affairs (VA) sites in Southern California. The clinics were both primary-care clinics with urgent-care components. One was a large, university-affiliated hospital, and the other was an urban outpatient clinic serving many indigent and homeless veterans.

Patients were eligible for inclusion in the RCT if they met all of the following criteria: (1) aged 18--65 years, (2) unaware of their HIV status, (3) had not received an HIV test in the past year, (4) had an appointment with a provider in the target clinic that day, (5) were proficient in English and (6) were competent to consent to the study.[@CR17]

Patients in the trial were on average 49.7 years old, 32% White, 43% African American, essentially all men, 9.6% were men who have sex with men, and the prevalence of undiagnosed HIV in the population was 0.398% (Table [1](#Tab1){ref-type="table"}).[@CR17] Age- and sex-specific incidence of future HIV in the patient population was based on previous models.[@CR4],[@CR8],[@CR26]--[@CR28]Table 1Input Variables and SourcesVariableBase case valueRangeDistribution^a^SourceDemographics Age, years49.740--60Normal[@CR17] Prevalence of undiagnosed HIV, %0.3980.1--5Beta[@CR17] Men who have sex with men, %9.60--25[@CR17]HIV test characteristics, % Sensitivity of traditional testing99.698--99.9Beta[@CR12] Specificity of traditional testing99.999499--100Beta[@CR12] Sensitivity of rapid testing99.698--100Beta<http://www.fda.gov/cber/faq/oraqckfaq.htm> Specificity of rapid testing99.999496--100DiscreteAssumed to be equal to traditional testing, [@CR47]Screening strategies Probability of having an HIV test, % Model A (traditional HIV counseling and testing)41.030.2--51.8Beta[@CR17] Model B (nurse-initiated screening with traditional counseling)84.576.7--92.3Beta[@CR17] Model C (nurse-initiated screening with streamlined counseling and rapid testing)89.382.5--96.1Beta[@CR17] Probability of receiving HIV test result (given test negative), % Model A35.318.9--51.7Beta[@CR17] Model B36.625.2--48.0Beta[@CR17] Model C89.382.1--96.5Beta[@CR17] Probability of receiving HIV test result (given test positive), % Model A9030--100BetaEstimate and range based on [@CR7],[@CR15],[@CR48] Model B9030--100BetaEstimate and range based on [@CR7],[@CR15],[@CR48] Model C10080--100BetaEstimate and range based on [@CR7],[@CR15],[@CR48] Costs, \$ HIV screening, negative test, \$Conventional screening12.419.30--15.50CMS reimbursement rates for the VA for CPT 86701 HIV-1 EIARapid test screening11.458.50--14.50Abbott Laboratories HIV screening, positive test, \$Conventional screening51.8738.90--64.84CMS reimbursement rates for the VA for CPT 86701 HIV-1 EIA and second EIA and CPT 86689 HIV-1 Western blotRapid test screening50.9138.18--63.64CMS reimbursement rates for the VA for CPT 86701 HIV-1 EIA and second EIA and CPT 86689 HIV-1 Western blot incorporating rapid test screening costPre-test counseling, \$Conventional counseling10.166.77--13.55GammaBased on 15 min (range 10--20 min) for an HIV counselor at a average salary of \$81,307Streamlined counseling5.000.30--9.69GammaBased on 7.38 min (standard deviation 6.9 min) for an HIV counselor at a average salary of \$81,307Post-test counseling for negative results, \$1.360.68--6.78Based on 2 min (range 1--10 min) for an HIV counselor at an average salary of \$81,307. Same cost for post-test counseling of negative results regardless of testing typePost-test counseling for positive results, \$13.5520.33--40.65Based on 20 min (range 10--60 min) for an HIV counselor at an average salary of \$81,307. Same cost for post-test counseling of positive results regardless of testing type^a^Indicates the distribution used in the probabilistic sensitivity analysis

HIV Testing and Receipt of Result Strategies {#Sec4}
--------------------------------------------

The strategies in our analysis reflected those of the RCT. In strategy Model A, patients were encouraged by a nurse to discuss their need for a HIV-screening test with their physician. If the patient and physician agreed on HIV screening, the test, as well as the pre- and post-test counseling, was based on standard pretest and posttest counseling performed by a trained counselor. HIV screening was performed using a HIV-1 serum enzyme-linked immunosorbent assay (EIA) test and, if positive, was followed by a repeat HIV-1 EIA test and a HIV-1 Western blot analysis. Per the published literature, we assumed traditional HIV testing had a sensitivity of 99.6% and a specificity of 99.9994%.[@CR12]

In the Model B strategy, the nurse recommended that the patient get screened for HIV and, if the patient agreed, they were then referred for traditional counseling/testing.

Model C involved the nurse recommending HIV screening to the patient. If the patient agreed to testing, then the patient was screened using an oral swab and the OraQuick® rapid screening test (OraSure Technologies, Inc, Bethlehem PA). Sensitivity of rapid HIV testing was based on OraQuick data and assumed to be 99.6%. The pre-test counseling was performed using a streamlined procedure[@CR1] that took approximately 7 min. Post-test counseling and follow-up of positive rapid HIV tests were performed in all strategies by a trained HIV counselor.

The trial indicated that traditional HIV counseling and testing (Model A) resulted in lower rates of testing (41%) and receipt of results given testing (35.3%) than did the nurse-initiated strategies (Models B and C), as shown in Table [1](#Tab1){ref-type="table"}. The most successful strategy was Model C, nurse-initiated routine screening with streamlined counseling and rapid HIV testing, in which approximately 90% of patients were tested and 90% of those tested received results (Table [1](#Tab1){ref-type="table"}).

Quality of Life {#Sec5}
---------------

The model incorporated adjustments for the quality of life associated with age-specific current health, HIV disease (asymptomatic HIV, symptomatic HIV and AIDS) and HAART.[@CR12] Utilities measure the patient's quality of life and were rated on a scale from 0 to 1, where 0 represents death and 1 ideal health. We multiplied utilities based on HIV-related health status and knowledge by age-specific utility weights derived from the Beaver Dam Health Outcomes Study.[@CR29]

Costs {#Sec6}
-----

We included the direct costs of medical care associated with physician and nurse time, HIV testing (initial and confirmatory tests) and counseling, follow-up and treatment of patients identified with HIV infection (Table [1](#Tab1){ref-type="table"}). We did not include costs associated with patient time. Costs of conventional HIV testing were derived from Centers for Medicare and Medicaid (CMS) reimbursement rates for the VA, while cost of rapid HIV testing was estimated from Abbott Laboratories. Costs of conventional pre-test and post-test counseling were based on the estimated time needed for a VA-based HIV counselor and using an average annual salary of \$81,300 (Table [1](#Tab1){ref-type="table"}). The time required for streamlined counseling prior to HIV testing was determined through a time-costing analysis in the RCT (average time = 7.4 min). Costs of HIV treatment and follow-up were based on our earlier analysis.[@CR12],[@CR13] We included age-specific medical expenditures unrelated to HIV care based on data from the Bureau of Labor Statistics (<http://www.bls.gov/cex/csxann05.pdf>). All costs were updated to 2007 dollars.[@CR30]

Sensitivity Analyses {#Sec7}
--------------------

We performed one-way and multi-way sensitivity analyses to account for important model assumptions and uncertainties. For variables derived from the randomized trial, ranges represent the 95% confidence intervals reported in the trial. For HIV natural history and clinical variables, our ranges for sensitivity analyses represent our judgment of the variation likely to be encountered in clinical practice on the basis of both the literature and discussion with experts. We varied costs in sensitivity analyses based on the standard deviation observed in the time-costing analysis, expert clinical judgment or assuming costs increased/decreased by 25%. A probabilistic sensitivity analysis was also performed, and its assumptions and findings are described in the [Appendix available online](#MOESM1){ref-type=""}.

RESULTS {#Sec8}
=======

We estimated the increase in life expectancy and quality-adjusted life expectancy that resulted from identification and treatment of HIV through the nurse-initiated screening (Models B and C) compared with traditional HIV counseling and testing. For an HIV-infected patient (49.7 years), Model B increased life expectancy by 0.64 years or 0.47 QALYs compared with Model A. If the nurse-initiated strategy included rapid testing and streamlined counseling (Model C), life expectancy was increased by 0.87 years or 0.63 QALYs compared to Model A (Fig. [2](#Fig2){ref-type="fig"}). Figure 2Effect of nurse-initiated screening strategies on life expectancy of HIV-infected patients. The effect on (**a**) undiscounted life expectancy and (**b**) undiscounted quality-adjusted life expectancy of using nurse-initiated testing for HIV infection, as compared with traditional counseling and testing (Model A). The solid line demonstrates the benefit to HIV-infected patients from incorporating streamlined counseling and rapid testing into the nurse-initiated strategy (Model C), while the dashed line represents nurse-initiated testing with traditional counseling (Model B).

Model A resulted in the lowest costs and effectiveness (Table [2](#Tab2){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}). Model B was more effective and costly, and Model C was the most effective and most costly (Table [2](#Tab2){ref-type="table"}). Note that lifetime costs in Table [2](#Tab2){ref-type="table"} include all direct medical costs for screening, counseling and treatment, as well as age-specific medical costs unrelated to HIV care, and that our estimated HIV prevalence of 0.398% was based on the trial results. Although Model B is more effective than Model A, Model C has a more favorable cost-effectiveness ratio than does Model B; thus Model B is eliminated by extended dominance (Table [2](#Tab2){ref-type="table"}). Extended dominance occurs when a more expensive strategy has a lower cost-effectiveness ratio than a competing (dominated) strategy; in this case, the more expensive alternative would always be preferable, since the outcome gain more than compensates for the cost. The additional gains in health benefit from Model C cost \$36,390/QALY, without consideration of the benefit from reduced transmission. Including these benefits resulted in a more favorable cost-effectiveness ratio of \$10,660/QALY (Table [2](#Tab2){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}). Table 2Health and Economic OutcomesOutcomeBenefits to partners excludedBenefits to partners includedModel AModel BModel CModel AModel BModel CPatients tested, %41.084.589.341.084.589.3Tested patients who receive results, %35.336.689.335.336.689.3Lifetime cost, \$48,65048,71048,72049,04049,06049,070Incr. cost, \$5313274LY, years18.833018.834818.835518.815318.817818.8187Incr. LY, years (life days)^a^0.0018 (0.65)0.0007 (0.25)0.0025 (0.91)0.0009 (0.34)Incremental cost-effectiveness, \$/LYExtended dominance^b^26,710^c^Extended dominance^b^9,240^c^QALY, years16.271416.272716.273216.253016.255116.2559Incr. QALY, years (days)^a^0.0013 (0.48)0.0005 (0.19)0.0021 (0.77)0.0008 (0.29)Incremental cost-effectiveness, \$/QALYExtended dominance^b^36,390^c^Extended dominance^b^10,660^ca^One life year (LY) = 365 life days; one quality-adjusted life year (QALY) = 365 quality-adjusted life days^b^Extended dominance = extended dominance occurs when a more expensive strategy has a more favorable cost-effectiveness ratio than a less expensive strategy; in this case, the more expensive alternative would always be preferable, since the outcome gain more than compensates for the cost^c^Because the Model B strategy is eliminated through extended dominance, the incremental cost-effectiveness ratios listed compare the Model C strategy directly to the Model A strategy. Model A = traditional counseling and testing; Model B = nurse-initiated screening with traditional counseling, Model C = nurse-initiated screening with streamlined counseling and rapid testingFigure 3Health and economic outcomes of testing and counseling strategies. (**a**) Benefits to partners excluded; (**b**) benefits to partners included.

Sensitivity Analyses {#Sec9}
--------------------

If the prevalence of unidentified HIV was lowered from 0.398% to 0.05%, the cost-effectiveness of Model C compared with Model A was less favorable at \$58,900/QALY (Fig. [4](#Fig4){ref-type="fig"}) without the benefits from reduced transmission; the cost-effectiveness was \$25,300/QALY with the benefit from reduced transmission included. Including the benefits to partners, Model C cost less than \$75,000/QALY as long as the prevalence of unidentified HIV was greater than 0.01%. Figure 4Sensitivity analysis of the effect of unidentified HIV prevalence on the incremental cost-effectiveness of the nurse-initiated rapid testing and streamlined counseling strategy (Model C) compared with traditional counseling and testing (Model A). The solid line includes the costs and benefits to partners, while the dashed line excludes these effects.

The benefits of Model C to patients are two-fold (i.e., the probability of a patient receiving an HIV test is increased, and given that HIV testing occurs, patients were more likely to receive these results). In sensitivity analyses we explored the effect of these two elements. If 89.3% of patients received their test results through rapid-testing and streamlined counseling (base-case estimates), then even if the HIV test acceptance rate was reduced to 40%, the cost-effectiveness ratio of Model C increased from the base case estimate of \$10,660/QALY only to \$13,240/QALY.

Sensitivity analyses with other model variables (Table [1](#Tab1){ref-type="table"}) did not change our results substantially. If the specificity of rapid testing was reduced to 96.1% and all positive tests were confirmed by an EIA, Western blot and viral load tests, Model C remained cost-effective at \$17,400/QALY.

DISCUSSION {#Sec10}
==========

We evaluated the cost-effectiveness of three strategies for implementing routine HIV screening. We used testing and counseling costs and receipt of test result outcomes from a previously performed randomized trial as inputs to a model-based analysis that estimated lifetime costs and health outcomes. This approach enabled us to assess the cost-effectiveness of these strategies by including both short- and long-term costs and health outcomes, in accordance with guidelines for the conduct of cost-effectiveness analyses.[@CR18]

Our main finding is that nurse-initiated routine screening with streamlined counseling and rapid HIV testing is cost-effective relative to traditional HIV counseling and testing. The increased effectiveness and the resulting cost-effectiveness occur because this strategy resulted in much higher rates of receipt of test results. This strategy, at \$36,390/QALY gained, met conventional thresholds for cost-effectiveness relative to Model A. When we considered the benefit to sexual partners from reduced transmission, rapid testing with streamlined counseling was even more favorable and cost \$10,660/QALY gained.

Although the CDC now recommends routine HIV screening in all health-care settings, implementation of screening remains a challenge, and few health-care systems have integrated screening into routine care. We believe that three elements of Model C contributed to the success of this strategy. First, the use of non-physician providers, in our case, nurses, substantially increased the rate of testing. This finding is consistent with a substantial body of literature that supports the use of non-physician providers for preventive care.[@CR31]--[@CR36] For example, a systematic review of 81 studies found that the most potent type of intervention to increase preventive services was organizational change, including designation of non-physician staff to perform specific prevention activities.[@CR36] Use of non-physician providers has the additional potential advantage of reducing per-person test costs by substitution of less expensive personnel. In our trial, aggregate costs were higher for the strategies that used nurse-initiated screening (Models B and C), but the increase in costs was related to the higher rates of testing, which offset the reduction in time and personnel costs.

The second important component of this strategy was streamlined counseling. With traditional testing and counseling, counseling costs are substantial, and for patients with negative tests are approximately 15 times higher than the cost of the HIV test itself.[@CR12] In the randomized trial, traditional pre-test counseling required 20 min on average. In contrast, streamlined pre-test counseling took 7 min, which resulted in a reduction in counseling costs of 65%. In the trial, there were no differences in HIV knowledge or in sexual risk behavior between the traditional or streamlined counseling groups.[@CR17] This result is consistent with that of the RESPECT-2 randomized trial of over 1,600 patients that compared rapid HIV testing and counseling in one visit to standard testing and counseling over two visits.[@CR37] However, the counseling for rapid testing in RESPECT-2 required 30 min and was likely both more costly and more intensive than our streamlined counseling. In addition, in post-hoc subgroup analyses in RESPECT-2, one time counseling appeared modestly less effective in men, suggesting that further evaluation of streamlined counseling is needed.

The third important component of this strategy was rapid testing. Rapid testing enabled patients to receive test results in approximately 20 min, whereas traditional testing required two visits and results were not available for 1 to 2 weeks. In our trial, the test costs were similar for rapid versus traditional testing. Our results about receipt of testing are consistent with a number of studies that indicate that rapid testing substantially increases the receipt of results[@CR16],[@CR38]--[@CR41] and is acceptable to patients.[@CR42],[@CR43] Recent studies have also indicated the potential economic benefits of rapid testing strategies.[@CR44],[@CR45]

Although the convenience of rapid testing is an important advantage, continued evaluation of the accuracy of rapid testing is necessary. In our trial, we had only one positive result, which was a true positive; thus, the false-positive rate was 0. However, a trial of testing in emergency department with rigorous quality control found a false-positive rate of approximately 3.1%.[@CR46] Patients should be counseled that positive rapid tests require confirmation.

Our trial was performed at two VA primary-care clinics in southern California, which raises the question of whether the results will be applicable in other settings. Although the rates of acceptance and receipt of result are likely to vary across settings, we believe the three components of our most effective strategy (initiation of testing by non-physician providers, use of streamlined counseling and rapid testing) are likely to be useful in other settings. Rapid testing has been evaluated in many environments, and use of non-physician providers has been studied in many prevention domains, as noted previously. The use of streamlined counseling addresses an important challenge to providers who have many competing demands on their time.

Our study has several limitations. As noted, our trial was performed in VA primary and urgent care settings, which have different patient populations than many primary or urgent care practices. In our trial, about 17% of patients approached for participation agreed to enter the study. Because this was a research study, informed consent was required, and the requirements for follow-up may have discouraged some patients from participating. Thus, the implications for implementation of screening outside a trial are not known. The cost-effectiveness of screening however would not be affected by the participation rate since a change in participation would increase/decrease costs and benefits proportionally. In addition, the VA populations we studied do not reflect the distributions or the risk groups in some other populations or settings. Because our results may not be generalizable to non-VA setting, further study in other settings would be helpful. In addition, longer term assessment of effectiveness of streamlined counseling would be useful; our follow-up did not extend beyond 4 weeks. Finally, our cost-effectiveness analysis assumed that identified patients would have access to HIV care, which is true in the VA, but may not hold in some settings. The benefit from screening would be less than we estimated if patients did not have full access to care.

We believe our study is relevant to primary care settings. Although the need for informed consent in our study precludes completely reproducing routine opt-out screening in a medical setting, we did offer testing routinely to all patients, which is in essence the CDC recommendation. We note, however, that there are potential barriers to implementation of nurse-based screening with rapid testing (Model C), which include lack of nursing time, prioritization of other tasks over HIV testing, lack of familiarity with rapid test procedures among nursing staff and the logistics of lengthening clinic encounters because patients must wait for test results. The importance of these barriers is likely to vary by clinical setting.

The current CDC guidelines recommend routine screening in health settings, a substantial change in policy from targeted risk-based screening. How best to implement routine screening is uncertain. We found that nurse-initiated screening with streamlined counseling and rapid testing (Model C) was an effective strategy to increase testing and receipt of results, and is cost-effective by conventionally accepted thresholds when compared with traditional counseling/testing. Our study suggests that this strategy has substantial promise as an approach for integrating routine HIV screening into the practice of primary care.
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